On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Details Plans to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene-therapy company, this morning announced that it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Per the update, Genprex President and COO Julien Pham, MD, MPH, will lead the company’s presentation at 11:10 a.m. … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Details Plans to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum”

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Taking Unique Gene Therapy Approach to Cancer Treatment

Genprex (NASDAQ: GNPX) is a clinical-stage, gene-therapy company focused on the advancement of its lead drug candidate, Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for non-small cell lung cancer (“NSCLC”). An article discussing the company reads, “Oncoprex is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, to target … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Taking Unique Gene Therapy Approach to Cancer Treatment”

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Developing Transformative Cancer Therapies

Related Editorial Gene therapies are gaining growing attention within the medical sector. Gene therapies help restore or replace the body’s damaged or missing genes. Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die. Gene therapies are also being developed for ailments such as migraines, skin conditions and hemophilia. Genprex Inc. … Continue reading “NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Developing Transformative Cancer Therapies”

Genprex Inc. (NASDAQ: GNPX) Aims to Reprogram the Course of Cancer with Gene Therapy Approach

Preclinical and clinical data indicate that Oncoprex immunogene therapy may be effective alone or in combination with targeted small molecule therapies; pre-clinical data also indicate potential effectiveness in combination with immunotherapies Lung cancer is the second-most common cancer and the leading cause of cancer deaths worldwide Genprex holds an exclusive license to more than 30 … Continue reading “Genprex Inc. (NASDAQ: GNPX) Aims to Reprogram the Course of Cancer with Gene Therapy Approach”

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Retains Pharmaceutical Branding Agency to Oversee Lead Drug Candidate Naming Process

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its 28-year history, Addison Whitney will oversee the proprietary and non-proprietary drug naming process for the company’s drug candidate for non-small … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Retains Pharmaceutical Branding Agency to Oversee Lead Drug Candidate Naming Process”

NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data in Lung Cancer Treatment Study

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody was recorded by its University of Texas MD Anderson Cancer Center collaborators in a lung cancer treatment study (http://nnw.fm/8E4bC). An article discussing the study reads, “The results of the study, which analyzed the … Continue reading “NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data in Lung Cancer Treatment Study”

NetworkNewsBreaks – Why Genprex Inc. (NASDAQ: GNPX) Is ‘One to Watch’

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is focused on the development of potentially life-changing technologies for cancer patients. A recent article discussing GNPX reads, “Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge … Continue reading “NetworkNewsBreaks – Why Genprex Inc. (NASDAQ: GNPX) Is ‘One to Watch’”

Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data on Non-Small Cell Lung Cancer Treatment

Genprex’s collaborators at MD Anderson reported positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody for the treatment of non-small cell lung cancer The TUSC2 gene, a tumor suppressor gene, is the active agent in Genprex’s Oncoprex immunogene therapy, the company’s lead drug candidate for the treatment of lung cancer … Continue reading “Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data on Non-Small Cell Lung Cancer Treatment”

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) at Forefront to Advance Innovative Developments in Fight Against Lung Cancers

Clinical-stage gene-therapy company Genprex (NASDAQ: GNPX) is at the forefront to advance innovative developments in the war against lung cancers, testing its trademarked Oncoprex immunogene therapy. A recent article discussing this reads, “Oncoprex’s phase I and II clinical-stage trial therapies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, … Continue reading “NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) at Forefront to Advance Innovative Developments in Fight Against Lung Cancers”

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Raising the Bar in Cancer Therapeutics

Related Editorial Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs underway looking to cure the incurable FDA expects 200 new gene and cell therapy INDs in … Continue reading “NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Raising the Bar in Cancer Therapeutics”

Contact us: 212.418.1217